Key result
Novel oral anticoagulants, including direct thrombin inhibitors and factor Xa inhibitors, provide effective and potentially safer alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation.
Population
Patients with atrial fibrillation
Design
Review
Authors
Loading...
Supports NOAC consideration where VKAs unsuitable in AF; leaves open optimal agent selection and long-term outcomes in underrepresented groups.
This review provides an overview of established and emerging anticoagulation strategies for stroke prevention and cardioversion in patients with atrial fibrillation.
Menezes et al. (2012) conducted a review in Atrial Fibrillation. Novel oral anticoagulants (direct thrombin inhibitors and factor Xa inhibitors) vs. Vitamin K antagonists or aspirin was evaluated. Novel oral anticoagulants, including direct thrombin inhibitors and factor Xa inhibitors, provide effective and potentially safer alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: